PE20080850A1 - Agentes que comprenden compuestos marcados con 18f y metodos relacionados - Google Patents

Agentes que comprenden compuestos marcados con 18f y metodos relacionados

Info

Publication number
PE20080850A1
PE20080850A1 PE2007001212A PE2007001212A PE20080850A1 PE 20080850 A1 PE20080850 A1 PE 20080850A1 PE 2007001212 A PE2007001212 A PE 2007001212A PE 2007001212 A PE2007001212 A PE 2007001212A PE 20080850 A1 PE20080850 A1 PE 20080850A1
Authority
PE
Peru
Prior art keywords
methyl
hydroxy
compounds
cyane
dioxo
Prior art date
Application number
PE2007001212A
Other languages
English (en)
Spanish (es)
Inventor
Lutz Lehmann
Ananth Srinivasan
Thomas Brumby
Detlef Sulzle
Timo Stellfeld
Keith Graham
Mylene Karramkam
Simon Ametamey
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06090166A external-priority patent/EP1897885A1/en
Priority claimed from EP07090079A external-priority patent/EP1985624A3/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20080850A1 publication Critical patent/PE20080850A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • C07K14/6555Somatostatins at least 1 amino acid in D-form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57545Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2007001212A 2006-09-08 2007-09-10 Agentes que comprenden compuestos marcados con 18f y metodos relacionados PE20080850A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06090166A EP1897885A1 (en) 2006-09-08 2006-09-08 Compounds and methods for F labelled agents
EP07090079A EP1985624A3 (en) 2007-04-23 2007-04-23 Single step method of radiofluorination of biologically active compounds or biomolecules

Publications (1)

Publication Number Publication Date
PE20080850A1 true PE20080850A1 (es) 2008-09-02

Family

ID=39031005

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001212A PE20080850A1 (es) 2006-09-08 2007-09-10 Agentes que comprenden compuestos marcados con 18f y metodos relacionados

Country Status (20)

Country Link
US (1) US8557776B2 (enExample)
EP (5) EP2289564A3 (enExample)
JP (2) JP5603074B2 (enExample)
KR (1) KR20090058553A (enExample)
AR (1) AR062726A1 (enExample)
AU (1) AU2007294124A1 (enExample)
BR (1) BRPI0716554A2 (enExample)
CA (2) CA2662449A1 (enExample)
CL (1) CL2007002620A1 (enExample)
CO (1) CO6150196A2 (enExample)
CR (1) CR10654A (enExample)
IL (4) IL197363A0 (enExample)
MA (1) MA30780B1 (enExample)
MX (1) MX2009002492A (enExample)
NO (1) NO20091428L (enExample)
PE (1) PE20080850A1 (enExample)
RU (1) RU2009112716A (enExample)
TN (1) TN2009000063A1 (enExample)
TW (1) TW200829277A (enExample)
WO (1) WO2008028688A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2662449A1 (en) 2006-09-08 2008-03-13 Bayer Schering Pharma Aktiengesellschaft Compounds and methods for 18f labeled agents
EA200901142A1 (ru) * 2007-03-01 2010-04-30 Байер Шеринг Фарма Акциенгезельшафт 18f фторбензоильные меченые биологически активные соединения в качестве диагностических визуализирующих средств, а также бензотриазол-1-илоксибензоильные, 2,5-(диоксопирролидин-1-илокси)бензоильные и триметиламмониобензоильные предшественники
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
WO2012094334A1 (en) * 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
WO2012170602A1 (en) * 2011-06-09 2012-12-13 Ge Healthcare Limited Distillation device and method
HUE061402T2 (hu) * 2013-03-15 2023-06-28 Cancer Targeted Tech Llc 18F-jelölt PSMA-célzott PET képalkotó ágensek elõállításának módszerei és diagnosztikai módszerek velük
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
US11518754B2 (en) 2017-02-17 2022-12-06 Yale University Radiolabeled pharmaceuticals and methods of making and using same
AU2018300069C1 (en) 2017-07-11 2025-11-20 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
MX2020001332A (es) 2017-08-03 2020-09-09 Synthorx Inc Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas.
JP2021522196A (ja) * 2018-04-20 2021-08-30 ザ ジェネラル ホスピタル コーポレイション 血液脳関門を越えて送達するためのアセチル化プロドラッグ
BR112021014415A2 (pt) 2019-02-06 2021-09-21 Synthorx, Inc. Conjugados de il-2 e métodos de uso dos mesmos
CN113150065B (zh) * 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
WO2022246118A2 (en) * 2021-05-20 2022-11-24 The Regents Of The University Of California Pet imaging tracers
WO2024204842A1 (ja) 2023-03-31 2024-10-03 日産化学株式会社 ピラゾール化合物及び有害生物防除剤

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002897A1 (en) * 1987-09-24 1989-04-06 The Administrators Of The Tulane Educational Fund Therapeutic peptides
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
US5084555A (en) 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
DE68928667T2 (de) * 1988-10-14 1998-10-01 Univ Tulane Peptide als arzneimittel
JP2846463B2 (ja) * 1989-06-02 1999-01-13 ジョージタウン・ユニバーシティー 抗ストレプトキナーゼ抗体の検出方法
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5244883A (en) 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
CN1110492C (zh) 1997-12-24 2003-06-04 沃泰克斯药物股份有限公司 天冬氨酰蛋白酶抑制剂的前药
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
ATE303988T1 (de) 1999-06-14 2005-09-15 Lilly Co Eli Inhibitoren von serin proteasen
US7115766B2 (en) 2000-11-30 2006-10-03 Indiana University Research & Technology Corp. Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds
GB0115927D0 (en) * 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
EP1497316B1 (en) * 2002-04-09 2006-07-05 Eli Lilly And Company Growth hormone secretagogues
CA2493471C (en) * 2002-08-09 2013-02-12 Yamanouchi Europe B.V. Compounds binding to p-selectin
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
CA2516685A1 (en) * 2003-02-20 2004-09-02 University Of South Florida Peptidomimetic inhibitors of stat3 activity and their medical uses
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
WO2006083424A2 (en) 2004-12-28 2006-08-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
US20100016295A1 (en) 2005-07-29 2010-01-21 Bayer Healthcare Llc Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity
US20080029548A1 (en) 2006-05-05 2008-02-07 Ann De Wree Fabric treatment dispensing package
CA2662449A1 (en) 2006-09-08 2008-03-13 Bayer Schering Pharma Aktiengesellschaft Compounds and methods for 18f labeled agents

Also Published As

Publication number Publication date
CR10654A (es) 2009-04-14
EP2455105B1 (en) 2016-02-17
EP2455105A2 (en) 2012-05-23
CO6150196A2 (es) 2010-04-20
EP2063918A2 (en) 2009-06-03
JP5722966B2 (ja) 2015-05-27
TN2009000063A1 (en) 2010-08-19
EP2289564A3 (en) 2012-11-14
TW200829277A (en) 2008-07-16
BRPI0716554A2 (pt) 2013-09-24
NO20091428L (no) 2009-06-03
IL211526A0 (en) 2011-05-31
EP2289564A2 (en) 2011-03-02
WO2008028688A2 (en) 2008-03-13
JP5603074B2 (ja) 2014-10-08
EP2455105A3 (en) 2012-09-05
CL2007002620A1 (es) 2008-05-30
WO2008028688A3 (en) 2008-11-13
CA2662449A1 (en) 2008-03-13
EP3056509A1 (en) 2016-08-17
JP2010503618A (ja) 2010-02-04
IL211527A0 (en) 2011-05-31
JP2014028813A (ja) 2014-02-13
IL197363A0 (en) 2011-08-01
EP2279759A2 (en) 2011-02-02
EP2279759A3 (en) 2013-04-17
AU2007294124A1 (en) 2008-03-13
MX2009002492A (es) 2009-08-28
US8557776B2 (en) 2013-10-15
RU2009112716A (ru) 2010-10-20
IL211033A0 (en) 2011-04-28
EP2063918B1 (en) 2014-02-26
CA2858907A1 (en) 2008-03-13
MA30780B1 (fr) 2009-10-01
AR062726A1 (es) 2008-11-26
KR20090058553A (ko) 2009-06-09
US20080292548A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
PE20080850A1 (es) Agentes que comprenden compuestos marcados con 18f y metodos relacionados
AR051839A1 (es) Metodo para preparar n-fenilpirazol -1- carboxamidas
PE20100809A1 (es) Inhibidores de glutamato de metaloproteinasas de matriz y agrecanasas
AR057987A1 (es) Compuestos agonistas de cb1 (receptor cannabinoide)
ES2494442T3 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico
RU2370485C2 (ru) Амидоацетонитрильные производные
BRPI0601896A (pt) composições que contêm microgéis e agentes espessantes
AR072099A1 (es) Compuestos para modulacion de cinasas
PE20090218A1 (es) Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas
PE20040374A1 (es) DERIVADOS DE ACIL-4-CARBOXIFENILUREA COMO INHIBIDORES DE LA GLUCOGENO FOSFORILASA a
MA31763B1 (fr) Inhibiteurs de kinase de type polo
AR066793A1 (es) Agentes de 3- ciano-4-triazolil fenilsoxazolina para el control de plagas de invertebrados
PE20040892A1 (es) Antagonistas del receptor muscarinico m3 de acetilcolina
BRPI0505798A (pt) eletrodo com núcleo de fluxo com flúor
PE20140381A1 (es) Dispersiones solidas extruidas por fusion que contienen un agente inductor de apoptosis
AR063449A1 (es) Proceso quimico para derivados de quinazolina, intermediarios
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
PE20090758A1 (es) Un proceso para la preparacion de compuestos de aminodiol protegidos con oxazolina, utiles como intermediarios para florfenicol
NO20076018L (no) Lagringsstabile opplosninger av optiske hvitemidler
PE20060427A1 (es) Derivados de pirazol como inhibidores de la union del glucagon y composiciones
PE20140792A1 (es) Composiciones farmaceuticas
BR112022013547A2 (pt) Métodos para potencializar a farmacocinética, para aumentar a concentração plasmática e a vigília ou diminuir a sonolência excessiva, e, composição
PE20061447A1 (es) Tigeciclina y metodos para preparar 9-aminominociclina
PE20040736A1 (es) Derivados de quinazolina como agentes anti-hiperalgesicos
PE20080949A1 (es) Azolilmetiloxiranos, su uso para combatir hongos fitopatogenos, asi como productos que los contienen

Legal Events

Date Code Title Description
FC Refusal